These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9396598)

  • 1. Puzzling over prion partners.
    Mitchell A
    Nat Med; 1997 Dec; 3(12):1322. PubMed ID: 9396598
    [No Abstract]   [Full Text] [Related]  

  • 2. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
    Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
    PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation.
    Burke CM; Walsh DJ; Mark KMK; Deleault NR; Nishina KA; Agrimi U; Di Bari MA; Supattapone S
    PLoS Pathog; 2020 Apr; 16(4):e1008495. PubMed ID: 32294141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structuring the puzzle of prion propagation.
    Eghiaian F
    Curr Opin Struct Biol; 2005 Dec; 15(6):724-30. PubMed ID: 16263262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A receptor for infectious and cellular prion protein.
    Martins VR
    Braz J Med Biol Res; 1999 Jul; 32(7):853-9. PubMed ID: 10454744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prions: proof of proteinaceous nature but problems with population polymorphisms.
    Griffiths PD
    Rev Med Virol; 2004; 14(6):341-3. PubMed ID: 15495195
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-genetic propagation of strain-specific properties of scrapie prion protein.
    Bessen RA; Kocisko DA; Raymond GJ; Nandan S; Lansbury PT; Caughey B
    Nature; 1995 Jun; 375(6533):698-700. PubMed ID: 7791905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell culture models of transmissible spongiform encephalopathies.
    Béranger F; Mangé A; Solassol J; Lehmann S
    Biochem Biophys Res Commun; 2001 Nov; 289(2):311-6. PubMed ID: 11716473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grand ideas floating freely. Conference on the new prion biology: basic science, diagnosis and therapy.
    Chesebro B
    EMBO Rep; 2002 Dec; 3(12):1123-6. PubMed ID: 12475924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
    Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
    Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human prion disease and human prion protein disease.
    Kitamoto T; Tateishi J
    Curr Top Microbiol Immunol; 1996; 207():27-34. PubMed ID: 8575204
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficient interspecies transmission of synthetic prions.
    Block AJ; Shikiya RA; Eckland TE; Kincaid AE; Walters RW; Ma J; Bartz JC
    PLoS Pathog; 2021 Jul; 17(7):e1009765. PubMed ID: 34260664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The state of the prion.
    Weissmann C
    Nat Rev Microbiol; 2004 Nov; 2(11):861-71. PubMed ID: 15494743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving views in prion glycosylation: functional and pathological implications.
    Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
    Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prions and prion diseases.
    Pergami P; Poloni TE; Corato M; Camisa B; Ceroni M
    Funct Neurol; 1999; 14(4):241-52. PubMed ID: 10713898
    [No Abstract]   [Full Text] [Related]  

  • 17. A transmembrane form of the prion protein in neurodegenerative disease.
    Hegde RS; Mastrianni JA; Scott MR; DeFea KA; Tremblay P; Torchia M; DeArmond SJ; Prusiner SB; Lingappa VR
    Science; 1998 Feb; 279(5352):827-34. PubMed ID: 9452375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper and Zinc Interactions with Cellular Prion Proteins Change Solubility of Full-Length Glycosylated Isoforms and Induce the Occurrence of Heterogeneous Phenotypes.
    Brim S; Groschup MH; Kuczius T
    PLoS One; 2016; 11(4):e0153931. PubMed ID: 27093554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible unfolding of infectious prion assemblies reveals the existence of an oligomeric elementary brick.
    Igel-Egalon A; Moudjou M; Martin D; Busley A; Knäpple T; Herzog L; Reine F; Lepejova N; Richard CA; Béringue V; Rezaei H
    PLoS Pathog; 2017 Sep; 13(9):e1006557. PubMed ID: 28880932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Species barrier in prion diseases: a kinetic interpretation based on the conformational adaptation of the prion protein.
    Kellershohn N; Laurent M
    Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):539-45. PubMed ID: 9729459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.